These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33594487)

  • 41. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
    Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
    PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between dipeptidyl peptidase-4 inhibitor use and risk of Parkinson's disease among patients with diabetes mellitus: a retrospective cohort study.
    Huang KH; Yang Y; Gau SY; Tsai TH; Lee CY
    Aging (Albany NY); 2024 Aug; 16(16):11994-12007. PubMed ID: 39177655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of fractures and diabetes medications: a nationwide cohort study.
    Choi HJ; Park C; Lee YK; Ha YC; Jang S; Shin CS
    Osteoporos Int; 2016 Sep; 27(9):2709-2715. PubMed ID: 27080708
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
    Komamine M; Kajiyama K; Ishiguro C; Uyama Y
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study.
    Kim YG; Jeon JY; Kim HJ; Kim DJ; Lee KW; Moon SY; Han SJ
    J Clin Med; 2018 Dec; 8(1):. PubMed ID: 30597861
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.
    Wilhite K; Reid JM; Lane M
    Ann Pharmacother; 2024 Jul; 58(7):685-689. PubMed ID: 37881914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
    Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF
    Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and DPP-4 Inhibitors: Population-Based Cohort Study.
    Dimakos J; Cui Y; Platt RW; Renoux C; Filion KB; Douros A
    Clin Pharmacol Ther; 2023 Sep; 114(3):712-720. PubMed ID: 37326010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
    Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
    J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of medication adherence in patients with type 2 diabetes mellitus.
    Curkendall SM; Thomas N; Bell KF; Juneau PL; Weiss AJ
    Curr Med Res Opin; 2013 Oct; 29(10):1275-86. PubMed ID: 23815104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
    Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
    BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.
    Chin HJ; Nam JH; Lee EK; Shin JY
    Medicine (Baltimore); 2017 Jun; 96(25):e7213. PubMed ID: 28640111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.
    Chang CH; Lu CH; Chung CH; Su SC; Kuo FC; Liu JS; Li PF; Huang CL; Chen KC; Ho LJ; Kuo CC; Chang CY; Lin MS; Liu YC; Chu NF; Lee CH; Hung YJ; Hsieh PS; Lin FH; Hsieh CH; Chien WC
    J Chin Med Assoc; 2022 Jul; 85(7):747-753. PubMed ID: 35648138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
    Lee SG; Lee HJ; Yoon MS; Kim DH
    JAMA Dermatol; 2019 Feb; 155(2):172-177. PubMed ID: 30624566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
    Chung YR; Ha KH; Kim HC; Park SJ; Lee K; Kim DJ
    Diabetes Metab J; 2019 Oct; 43(5):640-648. PubMed ID: 30877707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes.
    Siriyotha S; Lukkunaprasit T; Looareesuwan P; Nimitphong H; McKay GJ; Attia J; Thakkinstian A
    Cardiovasc Diabetol; 2022 Nov; 21(1):248. PubMed ID: 36397062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.